

# Supporting Information

## Three-Component, One-Pot Sequential Synthesis of *N*-Aryl, *N'*-Alkyl Barbiturates

Alessandro Volonterio, and Matteo Zanda

*Dipartimento di Chimica, Materiali ed Ingegneria Chimica “G. Natta” del Politecnico di Milano,  
via Mancinelli 7, I-20131 Milano, Italy, and C.N.R.- Istituto di Chimica del Riconoscimento  
Molecolare, Sezione “A. Quilico”, via Mancinelli 7, I-20131 Milano, Italy.*

[alessandro.volonterio@polimi.it](mailto:alessandro.volonterio@polimi.it)

### Table of Contents:

- S1-S3 General procedures for the synthesis of malonic acid monoesters **3a-c** and barbiturates **1a-o**.
- S4-S7 Characterization of 2-octyl-malonic acid monoethyl ester **3a**, carbodiimides **4a, 4c** and barbiturates **1a-o**.
- S8-S25  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra of 2-octyl-malonic acid monoethyl ester **3a**, carbodiimides **4a, 4c** and barbiturates **1a-o**.

**General Methods:** Commercially available reagent-grade solvents were employed without purification.  $^1\text{H}$  NMR spectra were run on spectrometers 400 or 500 MHz. Chemical shifts are expressed in ppm ( $\delta$ ), using tetramethylsilane (TMS) as internal standard for  $^1\text{H}$  and  $^{13}\text{C}$  nuclei ( $\delta_{\text{H}}$  and  $\delta_{\text{C}} = 0.00$ ), while  $\text{C}_6\text{F}_6$  was used as external standard ( $\delta_{\text{F}} 162.90$ ) for  $^{19}\text{F}$ .

**Materials:** carbodiimides **4a-c** were prepared according to the literature.<sup>1</sup>  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectral data of malonic acid mono-esters **3b**<sup>2</sup> and **3c**<sup>3</sup> and carbodiimide **4b**<sup>4</sup> were in agreement with those previously reported.

**General procedure for the synthesis of malonic acid monoesters 3a,b starting from benzyl ethylmalonate 5.** To a stirred solution of **5** (1 equiv.) in dry DMF (0.1 M solution) 1.1 equiv. of NaH (60% in weight oil dispersion) was added at 0 °C under nitrogen atmosphere and the mixture stirred for 30'. Neat alkyl bromide (1.2 equiv.) was added, the temperature left to reach rt and the mixture stirred over-night. Water was added and the resulting mixture was extracted with  $\text{Et}_2\text{O}$ . The combined organic layers were dried over anhydrous  $\text{NaSO}_4$ , filtered and concentrated under vacuum. The crude was dissolved in a 1:1 mixture of AcOEt/MeOH (0.1 M solution), a catalytic amount of  $\text{Pd}(\text{OH})_2/\text{C}$  was added and the mixture was stirred under dihydrogen atmosphere until total consumption of the starting material (TLC monitoring). The catalyst was filtered through a Celite pad, the organic solvent evaporated and the crude purified by flash chromatography.

**General procedure for the synthesis of 2-phenyl malonic acid mono-ethylester 3c starting from ethyl phenylacetate 6.** To a LDA (2.1 equiv.) solution in dry THF (0.25M solution) a solution of **6** (1 equiv.) in dry THF (0.3M solution) was added drop wise at – 60 °C under nitrogen atmosphere. After 1 h. at the same temperature an excess of solid  $\text{CO}_2$  was added and the mixture left to reach slowly rt. Most of the organic solvent was evaporated, the mixture acidified until pH 1 with a 1N aqueous HCl solution, extracted with AcOEt, the combined organic layers dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered, concentrated under vacuum and the crude purified by flash chromatography.

**General procedure for the synthesis of barbiturates 1a-e under  $\text{NaOH}$ |dioxane protocol.** To a stirred solution of malonic acid mono-esters **3** (1 equiv.) in dioxane (0.1M solution) carbodiimide **4** (1.1 equiv.) was added and the mixtures stirred at rt over-night. A 2N aqueous NaOH solution was added followed by neat benzyl halide **7** (4 equiv.) when the cyclization is

<sup>1</sup> Palomo, C.; Mestres, R. *Synthesis*, **1981**, 373-374.

<sup>2</sup> Ambrosie, L.; Chassagnard, C.; Revial, G.; D'Angelo, J. *Tetrahedron: Asymmetry* **1991**, 6, 407-410.

<sup>3</sup> Niwayama, S. *J. Org. Chem.* **2000**, 65, 5834-5836.

<sup>4</sup> Barvian, M. R.; Hollis Showalter, H. D.; Doherty, A. *Tetrahedron Lett.* **1997**, 38, 6799-6702.

complete (typically 10', TLC monitoring). After 1 h the solution was acidified with a 1N aqueous HCl solution, extracted with AcOEt, the combined organic layers dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated under vacuum and the crude purified by flash chromatography.

**General procedure for the synthesis of barbiturates **1f-o** under K<sub>2</sub>CO<sub>3</sub>|CH<sub>3</sub>CN protocol.**

In a sealed tube, carbodiimide **4** (1.1 equiv.) was added to a stirred solution of malonic acid mono-esters **3** (1 equiv.) in dioxane (0.1M solution) and the mixtures stirred at rt over-night. Solid anhydrous K<sub>2</sub>CO<sub>3</sub> (2.1 equiv.) followed by alkyl halide **7** (4 equiv.) were added and the mixture was heated at 120 °C. After the reaction is complete (typically 30' for highly reactive benzyl or allyl halides **7a-d,g** and 12 h for less reactive alkyl halides **7e,f,h,i**, TLC monitoring), the mixture was cooled to rt and water was added. The mixture was extracted with AcOEt, the combined organic layers dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated under vacuum and the crude purified by flash chromatography.

**2-Octyl-malonic acid monoethyl ester 3a:**  $R_f = 0.22$  (Hexane/AcOEt = 80:20);  $^1\text{H}$  NMR (400 MHz, CD<sub>3</sub>OD) δ 4.23 (q,  $J = 7.2$  Hz, 2H), 3.37 (t,  $J = 7.2$  Hz, 1H), 1.92 (m, 2H), 1.31 (m, 12H), 1.29 (t,  $J = 7.2$  Hz, 3H), 0.88 (t,  $J = 7.2$  Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz, CD<sub>3</sub>OD) δ 172.8, 171.5, 62.3, 53.2, 32.9, 30.4, 30.29, 30.23, 29.9, 28.35, 28.31, 23.6, 14.3; ESI ( $m/z$ ) 267.1 [M<sup>+</sup>+Na, (100)], 245.1 [M<sup>+</sup>+1, (68)].

**(4-Methoxy-benzyl)-(4-methoxyphenyl)-carbodiimide 4a:**  $R_f = 0.56$  (Hexane/AcOEt = 80:20); FTIR (nujol) ν 2118, 1512 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29 (d,  $J = 8.7$  Hz, 2H), 6.93 (d,  $J = 9.0$  Hz, 2H), 6.90 (d,  $J = 8.7$  Hz, 2H), 6.79 (d,  $J = 9.0$  Hz, 2H), 4.47 (s, 2H), 3.80 (s, 3H), 3.76 (s, 3H);  $^{13}\text{C}$  NMR (100.6 MHz, CDCl<sub>3</sub>) δ 159.2, 156.9, 138.3, 132.5, 130.3, 128.7, 124.4, 114.6, 114.1, 55.4, 55.2, 50.1.

**Methyl-(4-trifluoromethylphenyl)-carbodiimide 4c:**  $R_f = 0.63$  (Hexane/AcOEt = 80:20); FTIR (nujol) ν 2150, 1323 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) δ 7.52 (d,  $J = 8.4$  Hz, 2H), 7.14 (d,  $J = 8.4$  Hz, 2H), 3.20 (s, 3H);  $^{13}\text{C}$  NMR (100.6 MHz, CDCl<sub>3</sub>) δ 144.6, 126.4 (q,  $J = 3.8$  Hz), 123.7, 121.5, 32.1, the corresponding resonances of CF<sub>3</sub> group and of C<sub>α</sub> to the CF<sub>3</sub> group are obscured;  $^{19}\text{F}$  NMR (470.6 MHz, CDCl<sub>3</sub>) δ -63.1;.

**1-(Methoxy-benzyl)-3-(4-methoxyphenyl)-5-octyl-pyrimidine-2,4,6-trione 1a:**  $R_f = 0.40$  (Hexane/AcOEt = 70:30); FTIR (nujol) ν 1703, 1691 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41 (d,  $J = 8.7$  Hz, 2H), 7.05 (d,  $J = 9.0$  Hz, 2H), 6.97 (d,  $J = 9.0$  Hz, 2H), 6.83 (d,  $J = 8.7$  Hz, 2H), 5.05 (d,  $J = 13.9$  Hz, 1H), 4.98 (d,  $J = 13.9$  Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.60 (t,  $J = 5.5$  Hz, 1H), 2.15 (m, 2H), 1.23 (m, 12H), 0.89 (t,  $J = 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz, CDCl<sub>3</sub>) δ 168.7, 168.6, 159.9, 159.4, 151.5, 130.9, 129.3, 128.5, 126.9, 114.8, 113.9, 55.5, 55.2, 49.7, 44.8, 32.0, 31.8, 29.2, 29.1, 29.0, 25.9, 22.6, 14.0; ESI ( $m/z$ ) 489.1 [M<sup>+</sup>+Na, (48)], 467.1 [M<sup>+</sup>+1, (100)].

**5-Benzyl-5-ethyl-1-(4-methoxybenzyl)-3-phenyl-pyrimidine-2,4,6-trione 1b:**  $R_f = 0.45$  (Hexane/AcOEt = 80:20); FTIR (nujol) ν 1698, 1687 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40 (m, 4H), 7.33 (d,  $J = 7.6$  Hz, 2H), 7.22 (m, 1H), 7.11 (m, 2H), 6.95 (d,  $J = 7.9$  Hz, 2H), 6.83 (d,  $J = 7.6$  Hz, 2H), 6.81 (m, 1H), 4.98 (d,  $J = 13.7$  Hz, 1H), 4.86 (d,  $J = 13.7$  Hz, 1H), 3.81 (s, 3H), 3.38 (d,  $J = 12.7$  Hz, 1H), 3.24 (d,  $J = 12.7$  Hz, 1H), 2.28 (m, 2H), 0.89 (t,  $J = 7.6$  Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz, CDCl<sub>3</sub>) δ 171.5, 171.0, 159.3, 135.0, 134.5, 131.0, 129.5, 129.3, 129.0, 128.6, 128.3, 128.2, 127.6, 113.8, 59.7, 55.3, 46.1, 44.8, 33.3, 9.7; ESI ( $m/z$ ) 465.2 [M<sup>+</sup>+Na, (100)], 443.1 [M<sup>+</sup>+1, (87)].

**5-(4-Bromo-benzyl)-5-ethyl-1-(4-methoxybenzyl)-3-(4-methoxyphenyl)-pyrimidine-2,4,6-trione 1c:**  $R_f = 0.50$  (Hexane/AcOEt = 70:30); FTIR (nujol) ν 1700, 1695, 1683 cm<sup>-1</sup>;  $^1\text{H}$  NMR (500 MHz, CDCl<sub>3</sub>) δ 7.28 (d,  $J = 8.5$  Hz, 2H), 7.17 (d,  $J = 8.5$  Hz, 2H), 6.96 (d,  $J = 7.5$  Hz, 2H), 6.85 (d,  $J = 8.5$  Hz, 2H), 6.80 (d,  $J = 8.5$  Hz, 2H), 6.78 (m, 2H), 4.97 (d,  $J = 14.1$  Hz, 1H), 4.90 (d,  $J$

= 14.1 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.28 (d,  $J$  = 12.7 Hz, 1H), 3.21 (d,  $J$  = 12.7 Hz, 1H), 2.25 (m, 2H), 0.90 (t,  $J$  = 7.5 Hz, 3H);  $^{13}\text{C}$  NMR (125.7 MHz,  $\text{CDCl}_3$ )  $\delta$  171.2, 171.1, 159.9, 159.4, 150.5, 133.9, 131.6, 131.2, 130.9, 129.1, 128.2, 126.8, 121.6, 114.8, 113.8, 59.4, 55.9, 55.3, 44.8, 33.7, 9.63; ESI ( $m/z$ ) 573.2 [ $\text{M}^+ + \text{Na}$ , (45)], 551.1 [ $\text{M}^+ + 1$ , (100)].

**5-Ethyl-5-(9H-fluoren-9-yl)-1-(4-methoxybenzyl)-3-(4-methoxyphenyl)-pyrimidine-2,4,6-trione 1d:**  $R_f$  = 0.35 (Hexane/AcOEt = 70:30); FTIR (nujol)  $\nu$  1700, 1683  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.69 (d,  $J$  = 7.6 Hz, 1H), 7.63 (d,  $J$  = 7.6 Hz, 1H), 7.55 (d,  $J$  = 7.6 Hz, 1H), 7.43-7.34 (m, 4H), 7.24 (m, 1H), 7.01 (m, 2H), 6.86 (d,  $J$  = 8.7 Hz, 2H), 6.82 (d,  $J$  = 8.7 Hz, 2H), 6.84 (m, 2H), 5.06 (d,  $J$  = 13.5 Hz, 1H), 5.01 (d,  $J$  = 13.5 Hz, 1H), 4.71 (s, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 2.67 (q,  $J$  = 7.3 Hz, 2H), 0.93 (t,  $J$  = 7.3 Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  171.1, 168.9, 159.7, 159.4, 150.8, 142.2, 142.1, 141.9, 141.7, 131.3, 128.9, 128.2, 128.0, 126.9, 126.8, 126.6, 125.7, 124.7, 120.3, 120.2, 114.6, 113.8, 60.4, 55.4, 55.3, 54.2, 45.0, 32.6, 9.7; ESI ( $m/z$ ) 569.2 [ $\text{M}^+ + \text{Na}$ , (100)], 547.2 [ $\text{M}^+ + 1$ , (82)].

**1-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-5-octyl-5-(4-trifluoromethyl-benzyl)-pyrimidine-2,4,6-trione 1e:**  $R_f$  = 0.44 (Hexane/AcOEt = 80:20); FTIR (nujol)  $\nu$  1701, 1697, 1684  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.30 (d,  $J$  = 8.9 Hz, 2H), 7.28 (d,  $J$  = 8.4 Hz, 2H), 7.02 (d,  $J$  = 8.0 Hz, 2H), 6.94 (d,  $J$  = 8.4 Hz, 2H), 6.83 (d,  $J$  = 8.9 Hz, 2H), 6.70 (m, 2H), 4.96 (d,  $J$  = 13.6 Hz, 1H), 4.91 (d,  $J$  = 13.6 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.40 (d,  $J$  = 12.7 Hz, 1H), 3.28 (d,  $J$  = 12.7 Hz, 1H), 2.21 (m, 2H), 1.24 (m, 12H), 0.90 (t,  $J$  = 6.6 Hz, 3H);  $^{13}\text{C}$  NMR (125.7 MHz,  $\text{CDCl}_3$ )  $\delta$  171.2, 171.1, 159.9, 159.5, 150.4, 139.1, 131.1, 130.0, 129.0, 128.1, 126.7, 125.4 (q,  $J$  = 3.3 Hz), 124.0 (q,  $J$  = 271.7 Hz), 114.8, 113.8, 58.6, 55.5, 52.2, 45.2, 44.8, 40.6, 31.8, 29.4, 29.1, 29.0, 25.2, 22.6, 14.1, the corresponding resonance of  $\text{C}_\alpha$  to the  $\text{CF}_3$  group is obscured;  $^{19}\text{F}$  NMR (470.6 MHz,  $\text{CDCl}_3$ )  $\delta$  -63.6; ESI ( $m/z$ ) 647.3 [ $\text{M}^+ + \text{Na}$ , (100)], 625.3 [ $\text{M}^+ + 1$ , (45)].

**1-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-5-octyl-5-propyl-pyrimidine-2,4,6-trione 1f:**  $R_f$  = 0.60 (Hexane/AcOEt = 80:20); FTIR (nujol)  $\nu$  1699, 1688  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.41 (d,  $J$  = 8.9 Hz, 2H), 7.05 (d,  $J$  = 8.9 Hz, 2H), 6.99 (d,  $J$  = 8.9 Hz, 2H), 6.84 (d,  $J$  = 8.9 Hz, 2H), 5.07 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 2.02 (m, 2H), 1.18 (m, 14H), 0.89 (t,  $J$  = 7.0 Hz, 3H), 0.86 (t,  $J$  = 7.5 Hz, 3H);  $^{13}\text{C}$  NMR (125.7 MHz,  $\text{CDCl}_3$ )  $\delta$  172.1, 172.0, 159.8, 159.3, 151.0, 130.8, 129.3, 128.6, 127.2, 114.7, 113.8, 57.0, 55.5, 55.2, 44.7, 42.3, 40.6, 31.7, 29.4, 29.1, 29.0, 25.0, 22.6, 18.5, 14.0, 13.9; ESI ( $m/z$ ) 531.3 [ $\text{M}^+ + \text{Na}$ , (100)], 509.3 [ $\text{M}^+ + 1$ , (98)].

**1-(4-Methoxybenzyl)-5,5-dioctyl-3-phenyl-pyrimidine-2,4,6-trione 1g:**  $R_f$  = 0.47 (Hexane/AcOEt = 90:10); FTIR (nujol)  $\nu$  1700, 1685  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.46 (m, 3H), 7.40 (d,  $J$  = 8.6 Hz, 2H), 7.13 (d,  $J$  = 6.8 Hz, 2H), 6.82 (d,  $J$  = 8.6 Hz, 2H), 5.06 (s, 2H), 3.78 (s, 3H), 2.01 (m, 2H), 1.18 (m, 24H), 0.88 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$

172.0, 171.9, 159.4, 150.9, 134.7, 130.8, 129.4, 129.0, 128.6, 128.3, 113.8, 57.0, 55.2, 44.7, 40.4, 31.8, 29.4, 29.2, 29.1, 25.1, 22.6, 14.1; ESI (*m/z*) 571.4 [M<sup>+</sup>+Na, (100)], 549.4 [M<sup>+</sup>+1, (31)].

**5-Allyl-1-methyl-5-octyl-3-(4-trifluoromethyl-phenyl)-pyrimidine-2,4,6-trione 1h:** *R<sub>f</sub>* = 0.62 (Hexane/AcOEt = 80:20); FTIR (nujol)  $\nu$  1701, 1695 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.74 (d, *J* = 8.0 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 5.69 (m, 1H), 5.20 (m, 2H), 3.36 (s, 3H), 2.77 (m, 2H), 2.08 (m, 2H), 1.25 (m, 12H), 0.88 (t, *J* = 6.4 Hz, 3H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  171.3, 171.1, 150.5, 137.6, 130.8, 129.1, 126.6, (q, *J* = 3.2 Hz), 121.0, 57.5, 44.4, 30.3, 31.7, 29.5, 29.2, 29.1, 28.6, 25.4, 22.6, 14.0, the corresponding resonances of CF<sub>3</sub> group and of C<sub>α</sub> to the CF<sub>3</sub> group are obscured; ESI (*m/z*) 461.2 [M<sup>+</sup>+Na, (78)], 439.2 [M<sup>+</sup>+1, (34)], 307 (100).

**1-Methyl-5-octyl-5-propyl-3-(4-trifluoromethyl-phenyl)-pyrimidine-2,4,6-trione 1i:** *R<sub>f</sub>* = 0.48 (Hexane/AcOEt = 90:10); FTIR (nujol)  $\nu$  1700, 1695 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.75 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 3.38 (s, 3H), 2.04 (m, 4H), 1.25 (m, 14H), 0.92 (t, *J* = 6.8 Hz, 3H), 0.88 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 171.2, 150.6, 137.8, 131.4 (q, *J* = 32.6 Hz), 129.1, 126.6 (q, *J* = 3.0 Hz), 123.6 (q, *J* = 270.7 Hz), 57.4, 42.3, 40.2, 31.7, 29.5, 29.2, 29.1, 28.6, 25.4, 22.6, 18.8, 14.0, 13.9; ESI (*m/z*) 463.2 [M<sup>+</sup>+Na, (92)], 441.2 [M<sup>+</sup>+1, (100)].

**1-Methyl-5-octyl-5-(3-phenyl-propyl)-3-(4-trifluoromethyl-phenyl)-pyrimidine-2,4,6-trione 1j:** *R<sub>f</sub>* = 0.27 (Hexane/Et<sub>2</sub>O = 90:10); FTIR (nujol)  $\nu$  1708, 1698 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.75 (d, *J* = 8.4 Hz, 2H), 7.27 (m, 5H), 7.13 (d, *J* = 8.4 Hz, 2H), 3.37 (s, 3H), 2.61 (m, 2H), 2.13 (m, 2H), 2.05 (m, 2H), 1.56 (m, 2H), 1.24 (m, 12H), 0.89 (t, *J* = 6.4 Hz, 3H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  171.7, 171.6, 150.5, 141.0, 137.7, 129.1, 128.4, 128.3, 126.6 (q, *J* = 2.8 Hz), 126.2, 57.2, 40.4, 39.5, 35.7, 31.7, 29.4, 29.15, 29.10, 28.7, 27.3, 25.3, 22.6, 14.0, the corresponding resonances of CF<sub>3</sub> group and of C<sub>α</sub> to the CF<sub>3</sub> group are obscured; ESI (*m/z*) 539.2 [M<sup>+</sup>+Na, (37)], 517.2 [M<sup>+</sup>+1, (33)], 280 (100).

**5-Benzyl-1-(4-methoxybenzyl)-3-(4-methoxyphenyl)-5-phenyl-pyrimidine-2,4,6-trione 1k:** *R<sub>f</sub>* = 0.46 (Hexane/AcOEt = 70:30); FTIR (nujol)  $\nu$  1699, 1695 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.40 (m, 5H), 7.27 (d, *J* = 8.8 Hz, 2H), 7.24 (m, 1H), 7.16 (m, 4H), 6.92 (d, *J* = 9.2 Hz, 2H), 6.81 (d, *J* = 8.8 Hz, 2H), 6.80 (m, 2H), 5.01 (d, *J* = 13.6 Hz, 1H), 4.92 (d, *J* = 13.6 Hz, 1H), 3.90 (d, *J* = 12.8 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.79 (d, *J* = 12.8 Hz, 1H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  170.0, 169.9, 159.8, 159.3, 150.5, 138.3, 135.1, 130.8, 130.4, 129.2, 128.6, 128.5, 128.1, 127.5, 126.9, 126.5, 114.7, 113.8, 62.4, 55.5, 55.3, 45.2, 43.0; ESI (*m/z*) 543.1 [M<sup>+</sup>+Na, (100)], 521.2 [M<sup>+</sup>+1, (47)].

**5-Allyl-1-(4-methox-benzyl)-3-(4-methoxyphenyl)-5-phenyl-pyrimidine-2,4,6-trione 1l:** *R<sub>f</sub>* = 0.45 (Hexane/AcOEt = 70:30); FTIR (nujol)  $\nu$  1699, 1695 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$

7.36 (d,  $J = 8.4$  Hz, 2H), 7.31 (m, 3H), 7.25 (m, 2H), 7.01 (d,  $J = 8.8$  Hz, 2H), 6.96 (d,  $J = 8.8$  Hz, 2H), 6.82 (d,  $J = 8.4$  Hz, 2H), 5.74 (m, 1H), 5.24 (d,  $J = 17.2$  Hz, 1H), 5.14 (d,  $J = 10.4$  Hz, 1H), 5.08 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.19 (d,  $J = 6.8$  Hz, 2H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  169.5, 169.4, 159.9, 159.4, 150.9, 137.5, 131.9, 130.8, 129.3, 129.2, 128.6, 128.3, 127.1, 126.0, 114.7, 113.8, 61.4, 55.5, 55.3, 45.3, 40.8; ESI ( $m/z$ ) 493.2 [ $\text{M}^++\text{Na}$ , (75)], 471.1 [ $\text{M}^++1$ , (87)], 459.2 (100).

**1-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-5-propyl-pyrimidine-2,4,6-trione**

**1m:**  $R_f = 0.34$  (Hexane/Et<sub>2</sub>O = 90:10); FTIR (nujol)  $\nu$  1700, 1696, 1685 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.36 (d,  $J = 8.4$  Hz, 2H), 7.29 (m, 3H), 7.22 (m, 2H), 7.02 (d,  $J = 8.8$  Hz, 2H), 6.98 (d,  $J = 8.4$  Hz, 2H), 6.82 (d,  $J = 8.8$  Hz, 2H), 5.08 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 2.41 (m, 2H), 1.36 (m, 2H), 0.96 (t,  $J = 7.2$  Hz, 3H);  $^{13}\text{C}$  NMR (125.6 MHz,  $\text{CDCl}_3$ )  $\delta$  170.0, 169.8, 159.9, 159.4, 150.9, 138.2, 130.8, 129.3, 129.2, 128.4, 128.3, 127.1, 125.8, 114.7, 113.8, 61.6, 55.5, 55.3, 45.3, 39.3, 19.3, 14.2; ESI ( $m/z$ ) 495.2 [ $\text{M}^++\text{Na}$ , (21)], 473.2 [ $\text{M}^++1$ , (100)].

**5-Hexyl-1-(4-methoxybenzyl)-3,5-diphenyl-pyrimidine-2,4,6-trione 1n:**  $R_f = 0.54$  (Hexane/AcOEt = 80:20); FTIR (nujol)  $\nu$  1700, 1699, 1696 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45 (m, 3H), 7.37 (d,  $J = 8.9$  Hz, 2H), 7.30 (m, 3H), 7.23 (m, 2H), 7.11 (m, 2H), 6.82 (d,  $J = 8.9$  Hz, 2H), 5.10 (s, 2H), 3.80 (s, 3H), 2.43 (m, 2H), 1.27 (m, 8H), 0.88 (t,  $J = 6.8$  Hz, 3H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  169.8, 159.4, 150.8, 138.2, 134.7, 130.8, 129.4, 129.2, 129.1, 128.5, 128.3, 125.9, 113.9, 61.6, 55.3, 45.3, 37.3, 31.4, 29.4, 25.8, 22.6, 14.0; ESI ( $m/z$ ) 507.1 [ $\text{M}^++\text{Na}$ , (65)], 485.1 [ $\text{M}^++1$ , (32)], 296 (100).

**5-Allyl-1-methyl-5-phenyl-3-(4-trifluoromethyl-phenyl)-pyrimidine-2,4,6-trione 1o:**  $R_f = 0.41$  (Hexane/AcOEt = 80:20); FTIR (nujol)  $\nu$  1704, 1699, 1695 cm<sup>-1</sup>;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.74 (d,  $J = 8.4$  Hz, 2H), 7.38 (m, 5H), 7.26 (d,  $J = 8.4$  Hz, 2H), 5.80 (m, 1H), 5.29 (d,  $J = 17.2$  Hz, 1H), 5.22 (d,  $J = 10.0$  Hz, 1H), 3.41 (s, 3H), 3.22 (m, 2H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  169.4, 169.2, 150.4, 137.7, 137.2, 131.8, 131.5 (q,  $J = 32.8$  Hz), 129.5, 129.1, 128.9, 126.6 (q,  $J = 3.7$  Hz), 126.0, 123.7 (q,  $J = 273.1$  Hz), 121.4, 61.8, 41.0, 29.2; ESI ( $m/z$ ) 425.1 [ $\text{M}^++\text{Na}$ , (100)], 403.1 [ $\text{M}^++1$ , (97)].



































